You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEprosartan
Accession NumberDB00876  (APRD00950)
TypeSmall Molecule
GroupsApproved
DescriptionEprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.
Structure
Thumb
Synonyms
(e)-2-Butyl-1-(P-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
(e)-3-[2-N-Butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
(e)-Alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
Eprosartan
Éprosartan
Eprosartan
Eprosartanum
External Identifiers
  • SKF 108566
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TevetenTablet400 mg/1OralAbb Vie Inc.2010-05-242016-04-05Us
TevetenTablet600 mgOralBgp Pharma Ulc2001-05-25Not applicableCanada
TevetenTablet600 mg/1OralAbb Vie Inc.2010-05-242016-04-05Us
TevetenTablet400 mgOralBgp Pharma Ulc2000-09-08Not applicableCanada
Teveten Tablets 300 mgTablet300 mgOralSolvay Pharma Inc2000-09-082003-01-02Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eprosartan MesylateTablet, film coated600 mg/1OralMylan Pharmaceuticals Inc.2011-12-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EprozarINTAS Pharmaceuticals
FuturanMerck
Brand mixtures
NameLabellerIngredients
Teveten HctAbb Vie Inc.
Teveten PlusBgp Pharma Ulc
Salts
Name/CASStructureProperties
Eprosartan mesylate
ThumbNot applicableDBSALT000927
Categories
UNII2KH13Z0S0Y
CAS number133040-01-4
WeightAverage: 424.513
Monoisotopic: 424.145677956
Chemical FormulaC23H24N2O4S
InChI KeyOROAFUQRIXKEMV-LDADJPATSA-N
InChI
InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
IUPAC Name
4-({2-butyl-5-[(1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
SMILES
CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O
Pharmacology
IndicationFor the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors).
Structured Indications
PharmacodynamicsAngiotensin II, the principal pressor agent of the renin-angiotensin system, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme [kininase II]. It is responsible for effects such as vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Eprosartan selectively blocks the binding of angiotensin II to the AT1 receptor, which in turn leads to multiple effects including vasodilation, a reduction in the secretion of vasopressin, and reduction in the production and secretion of aldosterone. The resulting effect is a decrease in blood pressure.
Mechanism of actionEprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Eprosartan does not exhibit any partial agonist activity at the AT1 receptor. Its affinity for the AT1 receptor is 1,000 times greater than for the AT2 receptor. In vitro binding studies indicate that eprosartan is a reversible, competitive inhibitor of the AT1 receptor. Eprosartan has also been shown to bind to AT1 receptors both presynaptically and synaptically. Its action on presynaptic AT1 receptors results in the inhibition of sympathetically stimulated noradrenaline release. Unlike ACE inhibitors, eprosartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough).
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Related Articles
AbsorptionAbsolute bioavailability following a single 300 mg oral dose of eprosartan is approximately 13%. Administering eprosartan with food delays absorption.
Volume of distributionNot Available
Protein bindingPlasma protein binding of eprosartan is high (approximately 98%) and constant over the concentration range achieved with therapeutic doses.
Metabolism

Eprosartan is not metabolized by the cytochrome P450 system. It is mainly eliminated as unchanged drug. Less than 2% of an oral dose is excreted in the urine as a glucuronide.

Route of eliminationNot Available
Half lifeThe terminal elimination half-life of eprosartan following oral administration is typically 5 to 9 hours.
ClearanceNot Available
ToxicityThere was no mortality in rats and mice receiving oral doses of up to 3000 mg eprosartan/kg and in dogs receiving oral doses of up to 1000 mg eprosartan/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Eprosartan Action PathwayDrug actionSMP00159
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Eprosartan.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Eprosartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Eprosartan.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Eprosartan.Approved, Withdrawn
AmbrisentanEprosartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineEprosartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Eprosartan.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Eprosartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Eprosartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Eprosartan is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Eprosartan is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Eprosartan.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Eprosartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Eprosartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Eprosartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Eprosartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Eprosartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Eprosartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Eprosartan.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benoxaprofen.Withdrawn
BepridilEprosartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Eprosartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Eprosartan.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Betulinic Acid.Investigational
BimatoprostEprosartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Eprosartan.Approved
BortezomibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Eprosartan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Eprosartan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Eprosartan.Approved
BromfenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bupivacaine.Approved, Investigational
BupranololEprosartan may increase the hypotensive activities of Bupranolol.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Eprosartan.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Eprosartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Eprosartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Eprosartan.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Celecoxib.Approved, Investigational
CeliprololEprosartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Eprosartan.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Eprosartan.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Cilnidipine.Approved
CiprofloxacinEprosartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Eprosartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Conivaptan.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Eprosartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Eprosartan is combined with Curcumin.Investigational
CyclosporineEprosartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Eprosartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Eprosartan is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Eprosartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Eprosartan.Investigational
DebrisoquinEprosartan may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineEprosartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eprosartan.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Eprosartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diclofenamide.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diflunisal.Approved
DihydralazineEprosartan may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Eprosartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Eprosartan.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Eprosartan.Approved
DrospirenoneEprosartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Droxicam.Approved
DuloxetineEprosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Eprosartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ebselen.Investigational
EfonidipineEprosartan may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Eprosartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Eprosartan.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Eprosartan.Approved
EpoprostenolEprosartan may increase the hypotensive activities of Epoprostenol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Eprosartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etanercept.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Eprosartan is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Eprosartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Eprosartan.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Eprosartan.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Eprosartan.Approved
GuanethidineEprosartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Eprosartan.Approved, Investigational
HexamethoniumEprosartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Eprosartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Eprosartan is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Eprosartan.Approved
HydralazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Eprosartan.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Eprosartan is combined with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Eprosartan.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Eprosartan.Approved
IndenololEprosartan may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indoprofen.Withdrawn
IndoraminEprosartan may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Eprosartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Eprosartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Eprosartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Eprosartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Kebuzone.Experimental
KetanserinEprosartan may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Eprosartan.Approved
LacidipineEprosartan may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Eprosartan.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Eprosartan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Levobupivacaine.Approved
LevodopaEprosartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Eprosartan.Approved
LofexidineEprosartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Eprosartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lumiracoxib.Approved, Investigational
MacitentanEprosartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Magnesium salicylate.Approved
ManidipineEprosartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Eprosartan.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Eprosartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Eprosartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Metamizole.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Eprosartan.Approved
MethohexitalMethohexital may increase the hypotensive activities of Eprosartan.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eprosartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Eprosartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Eprosartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Eprosartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Eprosartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Eprosartan.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Eprosartan.Approved, Investigational
MetyrosineEprosartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilEprosartan may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Eprosartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Eprosartan.Approved
MizoribineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Eprosartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Eprosartan.Approved
MorphineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Morphine.Approved, Investigational
MoxonidineEprosartan may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Eprosartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Naftifine.Approved
NaftopidilEprosartan may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Eprosartan is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Eprosartan.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Eprosartan.Approved
NicorandilNicorandil may increase the hypotensive activities of Eprosartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Niflumic Acid.Approved
NiguldipineEprosartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineEprosartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Eprosartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Eprosartan.Approved
NitrendipineEprosartan may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Eprosartan.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Eprosartan.Approved
ObinutuzumabEprosartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Eprosartan.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Eprosartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Eprosartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxaprozin.Approved
OxprenololEprosartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Eprosartan is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Eprosartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Eprosartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
PentoliniumEprosartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Eprosartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Eprosartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Eprosartan.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Eprosartan.Approved
PhenoxybenzamineEprosartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Eprosartan.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Eprosartan.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pimecrolimus.Approved, Investigational
PinacidilEprosartan may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pipamperone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Eprosartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Eprosartan.Withdrawn
PolythiazideEprosartan may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Eprosartan.Approved
PrimidonePrimidone may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Eprosartan.Approved, Investigational
PTC299The risk or severity of adverse effects can be increased when Eprosartan is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Eprosartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Eprosartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Eprosartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Eprosartan.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Eprosartan.Approved
RilmenidineEprosartan may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Eprosartan is combined with Riociguat.Approved
RisperidoneEprosartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabEprosartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Eprosartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salsalate.Approved
SaprisartanEprosartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Eprosartan.Approved, Investigational, Vet Approved
SelexipagEprosartan may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Eprosartan.Approved, Investigational
SitaxentanEprosartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Eprosartan.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Eprosartan.Approved
SRT501The risk or severity of adverse effects can be increased when Eprosartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Eprosartan is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Eprosartan.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Temocapril.Experimental, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Teriflunomide.Approved
TerlipressinEprosartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Thioridazine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tiaprofenic acid.Approved
TiboloneEprosartan may increase the hypotensive activities of Tibolone.Approved
TicrynafenEprosartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Eprosartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Eprosartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eprosartan.Approved
TolazolineTolazoline may increase the hypotensive activities of Eprosartan.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Eprosartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Eprosartan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Eprosartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Eprosartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Eprosartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Eprosartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Eprosartan.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Eprosartan.Approved
TrichlormethiazideEprosartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinEprosartan may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanEprosartan may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Eprosartan.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Eprosartan.Approved, Investigational
UnoprostoneEprosartan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Eprosartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Eprosartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.Approved
VinpocetineEprosartan may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineEprosartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Eprosartan.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zomepirac.Withdrawn
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Richard T. Matsuoka, Peng Liu, “Process for preparing eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates.” U.S. Patent US6294675, issued June, 1992.

US6294675
General References
  1. Ruilope L, Jager B, Prichard B: Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. 2001;10(4):223-9. [PubMed:11800061 ]
  2. Hedner T: The clinical profile of the angiotensin II receptor blocker eprosartan. J Hypertens Suppl. 2002 Jun;20(5):S33-8. [PubMed:12184062 ]
  3. Puig JG, Lopez MA, Bueso TS, Bernardino JI, Jimenez RT: Clinical profile of eprosartan. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. [PubMed:12766389 ]
  4. Ruilope L, Jager B: Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003 Jan;4(1):107-14. [PubMed:12517247 ]
  5. de la Sierra A, Ram CV: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3. doi: 10.1185/030079907X260692. [PubMed:18093407 ]
  6. Blankestijn PJ, Rupp H: Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. [PubMed:18855637 ]
External Links
ATC CodesC09CA02C09DA02
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (1.09 MB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9863
Blood Brain Barrier-0.6931
Caco-2 permeable-0.6261
P-glycoprotein substrateSubstrate0.8011
P-glycoprotein inhibitor INon-inhibitor0.8577
P-glycoprotein inhibitor IINon-inhibitor0.9574
Renal organic cation transporterNon-inhibitor0.7673
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.5798
CYP450 2C9 inhibitorNon-inhibitor0.6617
CYP450 2D6 inhibitorNon-inhibitor0.8325
CYP450 2C19 inhibitorNon-inhibitor0.6234
CYP450 3A4 inhibitorNon-inhibitor0.6086
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.644
Ames testNon AMES toxic0.7313
CarcinogenicityNon-carcinogens0.9454
BiodegradationNot ready biodegradable0.6117
Rat acute toxicity2.4288 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9464
hERG inhibition (predictor II)Non-inhibitor0.8827
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral600 mg/1
TabletOral400 mg
TabletOral400 mg/1
TabletOral600 mg
TabletOral600 mg/1
TabletOral
TabletOral300 mg
Prices
Unit descriptionCostUnit
Teveten hct 600-12.5 mg tablet3.52USD tablet
Teveten hct 600-25 mg tablet3.42USD tablet
Teveten 600 mg tablet3.19USD tablet
Teveten 400 mg tablet2.83USD tablet
Teveten 400 mg tiltab1.24USD tablet
Teveten 600 mg Tablet1.18USD tablet
Teveten 400 mg Tablet0.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2115170 No2004-05-252012-08-12Canada
CA2250395 No2005-09-062017-03-26Canada
US5185351 No1993-02-092010-02-09Us
US5656650 No1994-08-122014-08-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248-250 °C (mesylate form)Not Available
water solubilityInsoluble (mesylate form)Not Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00866 mg/mLALOGPS
logP3.57ALOGPS
logP3.8ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.63ChemAxon
pKa (Strongest Basic)6.93ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.42 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity117.02 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoic acids. These are organic Compounds containing a benzene ring which bears at least one carboxyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentBenzoic acids
Alternative Parents
Substituents
  • Benzoic acid
  • Trisubstituted imidazole
  • Phenylmethylamine
  • Imidazolyl carboxylic acid derivative
  • Benzoyl
  • 1,2,5-trisubstituted-imidazole
  • N-substituted imidazole
  • Dicarboxylic acid or derivatives
  • Heteroaromatic compound
  • Thiophene
  • Imidazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Heusser K, Vitkovsky J, Schmieder RE, Schobel HP: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Auton Neurosci. 2003 Aug 29;107(1):45-51. [PubMed:12927226 ]
  3. Gremmler B, Kunert M, Schleiting H, Ulbricht LJ: Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. Eur J Heart Fail. 2000 Jun;2(2):183-7. [PubMed:10856732 ]
  4. Suzuki G, Mishima T, Tanhehco EJ, Sharov VG, Todor A, Rostogi S, Gupta RC, Chaudhry PA, Anagnostopoulos PV, Nass O, Goldstein S, Sabbah HN: Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol. 2003 Jan;138(2):301-9. [PubMed:12540520 ]
  5. Ilson BE, Martin DE, Boike SC, Jorkasky DK: The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol. 1998 May;38(5):437-41. [PubMed:9602957 ]
  6. Nap A, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA: Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan. Eur J Pharmacol. 2003 May 23;469(1-3):117-24. [PubMed:12782193 ]
  7. Hedner T: The clinical profile of the angiotensin II receptor blocker eprosartan. J Hypertens Suppl. 2002 Jun;20(5):S33-8. [PubMed:12184062 ]
  8. Puig JG, Lopez MA, Bueso TS, Bernardino JI, Jimenez RT: Clinical profile of eprosartan. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. [PubMed:12766389 ]
  9. Ruilope L, Jager B: Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003 Jan;4(1):107-14. [PubMed:12517247 ]
  10. de la Sierra A, Ram CV: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3. doi: 10.1185/030079907X260692. [PubMed:18093407 ]
  11. Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ: ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001 May;141(5):800-7. [PubMed:11320369 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23